August 6, 2019 – CeloNova BioSciences, Inc. (CeloNova), a global medical device company and manufacturer of the proprietary Polyzene™-F nanocoating technology, currently used to surface coat its novel COBRA PzF NanoCoated Coronary Stent (NCS), today announced appointment of seasoned medical device executive Carl J. St. Bernard as President and Chief Executive Officer to support the company’s expected near-term commercial growth.
St. Bernard joins the company from Tryton Medical where he held the role of President and CEO, leading the company’s commercialization efforts in the highly competitive coronary stent market. St. Bernard also has an extensive track record growing businesses across a variety of fields including pharmaceuticals, consumer health products and diagnostic markets. St. Bernard’s prior experience includes Vice President at Johnson & Johnson Vision (formerly Abbott Medical Optics), Vice President of North American Marketing & Sales for LifeCell and Vice President at Cordis where he led the commercial operations for the cardiovascular and endovascular businesses in the U.S.
Read more here.